Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Depomed, Inc.
Depomed Initiates Phase 3 Program in Menopausal Hot Flashes
October 4th, 2008
Depomed, Inc. (NASDAQ:DEPO) announced the enrollment and dosing of the first patient in Breeze 1, the first of two pivotal Phase 3 clinical trials in Depomed's registration program for Gabapentin GR(R) for the treatment of menopausal hot flashes. "We believe that Gabapentin GR could become the first single-agent, safe, effective, non-hormonal and non-antidepressant treatment to address menopausal hot flashes, one of the largest unmet needs in women's health. The significant decline in annual prescriptions for hormone replacement treatments by forty million since the Women's Health Initiative trials were stopped in 2002 speaks to that need," said Michael Sweeney, M.D.,...
Source: Law & Health Weekly (2008-10-04)
|
